Wegovy vs Mounjaro: Compare Differences & Prices

When considering prescription treatments like Wegovy and Mounjaro for weight loss, it’s important to understand the possible side effects that can come with each medication. Both medicines are injectable drugs used alongside diet and exercise to help manage weight, but they contain different active ingredients and interact slightly differently with the body. Wegovy contains semaglutide, while Mounjaro contains tirzepatide. Both drugs work by affecting hormones that control hunger and feelings of fullness, but Mounjaro has the added action of mimicking an additional hormone involved in appetite regulation.

The most common side effects for both Wegovy and Mounjaro are related to digestion and tend to be mild to moderate in nature. Here are some of the main mild side effects reported with each medication:

• Digestive issues: Nausea, diarrhea, constipation, vomiting, and indigestion are frequently experienced by people taking either medication. These symptoms happen because the drugs slow down how quickly food leaves the stomach, which helps people feel fuller longer but can also cause stomach discomfort.

• Low energy or fatigue: Some people on Wegovy have reported feeling unusually tired, while others have experienced headaches or dizziness. Fatigue and dizziness have also been noted with Mounjaro.

• Common cold-like symptoms and stomach flu: While these are less frequently connected to the treatment, they have been seen in people using either drug.

Severity can vary, but most side effects tend to be more noticeable at the beginning of treatment and may lessen as the body adjusts. Injection site reactions—such as mild redness, swelling, or itching—can also occur with both drugs but are generally temporary.

While mild digestive problems are the most likely side effects, it’s also important to be aware of more serious, though less common, risks. Both Wegovy and Mounjaro carry warnings about some severe side effects:

• Low blood sugar (hypoglycemia): This is a concern, particularly for people also taking other diabetes medications, as these drugs can lower blood sugar levels.

• Pancreatitis and gallbladder issues: Reports include inflammation of the pancreas (pancreatitis), gallbladder inflammation, and formation of gallstones. Symptoms can include severe stomach pain and should be reported to a doctor right away.

• Severe gastrointestinal reactions: Stomach problems can, in rare cases, lead to more serious issues such as dehydration or kidney problems, usually as a result of ongoing vomiting or diarrhea.

• Thyroid cancer risk: Both drugs have a warning about an increased risk of a type of thyroid cancer, based on findings from animal studies. This risk is not confirmed in humans, but people with a personal or family history of certain types of thyroid cancer or specific genetic syndromes should not use these medications.

Beyond these effects, each medication has its own set of warnings. For example, Wegovy carries an extra warning for people with depression or suicidal thoughts. Both drugs require caution if you have a history of severe stomach issues, pancreas or kidney problems, or certain vision changes. Pregnant women, those planning pregnancy, or breastfeeding mothers should not use either medication.

It’s worth noting that in clinical trials, mild to moderate side effects were experienced by the majority of users—between 77% and 79% of people in studies on weight loss injectables like these—and a small percentage (about 6–8%) needed to stop taking the drug because of side effects. If side effects occur, it’s important not to stop medication abruptly but to consult your healthcare provider for guidance. They may be able to suggest ways to manage symptoms or adjust your treatment if needed.

Both Wegovy and Mounjaro have similar safety profiles in terms of the types and frequency of common side effects, with digestive issues leading the list, but the exact experience can differ from one person to another. The decision on whether to use one over the other should always be made in consultation with a healthcare provider, taking into consideration your personal health history, the side effect profile, other medications you may be taking, and your health goals.

Wegovy and Mounjaro are both injectable medications that can help with weight loss, but they are approved for somewhat different medical conditions. Wegovy contains the active ingredient semaglutide and is specifically approved for long-term weight management in adults and some children aged 12 and older who have obesity or are overweight with certain weight-related health conditions. In addition to helping with weight loss, Wegovy is also approved to reduce the risk of major heart problems such as heart attack or stroke in adults who have both obesity or overweight and existing heart disease. Recently, it has also gained accelerated approval for treating a specific type of liver disease—noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver scarring.

Mounjaro contains the active ingredient tirzepatide and is mainly approved for managing blood sugar levels in adults with type 2 diabetes. While Mounjaro is not officially approved for general weight loss or long-term weight management, doctors can prescribe it off-label for this purpose, and studies have shown that it leads to significant weight loss. It is important to know that Mounjaro is not currently approved for use in children for any condition.

To summarize how these two drugs are used:

• Wegovy is approved for:

  • Long-term weight management in adults and eligible children (over age 12) with obesity or overweight and at least one health issue related to weight

  • Reducing the risk of major heart events in adults with cardiovascular disease and obesity or overweight

  • Treating MASH (a kind of liver disease) in adults with significant liver scarring

• Mounjaro is approved for:

  • Managing blood sugar in adults with type 2 diabetes

  • It can be prescribed “off label” for weight loss in adults, but this is not its official use

For people living with diabetes, Mounjaro can be a good option as its primary focus is blood sugar control, and it also promotes weight loss as a secondary benefit. However, if your main goal is losing weight—especially in the context of other health conditions like high blood pressure, high cholesterol, or existing heart disease—Wegovy has broader and more direct approvals for these uses. Wegovy is also the only one of the two approved to reduce the risk of serious heart events and to treat certain liver conditions related to weight.

Neither Wegovy nor Mounjaro currently has a generic version available, and both are given as weekly injections. The choice between the two should be made with your doctor, based on your specific health needs. If you need help managing type 2 diabetes with added weight loss, Mounjaro may be recommended. If your focus is primarily on losing weight, especially when combined with other weight-related or heart health conditions, Wegovy might be more suitable. Pediatric weight loss, meanwhile, is only an official indication for Wegovy among children ages 12 and up.

It's essential to consider these differences in approved uses because insurance coverage and eligibility will often depend on the condition being treated. Always consult a healthcare provider to discuss your personal health goals and medical history before starting one of these medications.